ArticlePreventive medicine2025
Relationship between an adult-use Cannabis law and Cannabis use by type in a cohort of New Jersey young adults.
Article in Preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rapid tobacco surveillance among young people in six states: Methods and findings from the Center for Rapid Surveillance of Tobacco Youth and Young Adult Cohort.Preventive medicine reports · 2026Article
- Adult-use cannabis legalization in the united states: a scoping review of outcome monitoring recommendations.BMC public health · 2025Article
- Vaping ΔExpert review of clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesLimited research has evaluated the impact of cannabis policies on young adult cannabis use, after full implementation (retail outlets opened), nor on cannabis product type. This study examined the relationship between adult-use cannabis retail sales in New Jersey (United States) and young adult cannabis use by type.
methodsData on New Jersey young adults (18-23 years) were from the Policy Communication and Evaluation (PACE) New Jersey Study. Generalized estimating equations models estimated differences in prevalence of ever and past 30-day use of cannabis and sub-types before (Waves 1-3 [March-November 2021], n = 1439) and after (Wave 4 [June-July 2022], n = 1127) adult-use retail sales began.
resultsEver cannabis use among New Jersey young adults was higher in the post-retail sales period than pre-sales (58.1 % vs. 48.9 %, p < 0.01). The odds of ever cannabis use were 42 % higher (95 % CI = 32 %-54 %) in the post-retail period. Ever use of dried herb (post vs. pre: 44.4 % vs. 38.5 %, p < 0.01), drinks (7.0 % vs. 4.8 %, p < 0.01), edibles (45.9 % vs. 35.6 %, p < 0.01), and topicals (6.4 % vs. 4.6 %, p < 0.05), and past 30-day edible use (11.8 % vs. 9.0 %, p = 0.01) were higher post-retail; use of other product types did not differ.
conclusionsCannabis use overall and among certain subtypes (e.g., edibles) increased among New Jersey young adults in the three months after adult-use cannabis retail sales began, demonstrating that increased access to legal cannabis for sale may encourage use. Continued monitoring is needed over longer follow-up periods in New Jersey and other states legalizing cannabis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.